Show simple item record

dc.contributor.authorFerreri, A
dc.contributor.authorCwynarski, K
dc.contributor.authorPulczynski, E
dc.contributor.authorPonzoni, M
dc.contributor.authorDeckert, M
dc.contributor.authorPoliti, L
dc.contributor.authorTorri, V
dc.contributor.authorFox, C
dc.contributor.authorRosée, P
dc.contributor.authorSchorb, E
dc.contributor.authorAmbrosetti, A
dc.contributor.authorRoth, A
dc.contributor.authorHemmaway, C
dc.contributor.authorFerrari, A
dc.contributor.authorLinton, Kim M
dc.contributor.authorRudà, R
dc.contributor.authorBinder, M
dc.contributor.authorPukrop, T
dc.contributor.authorBalzarotti, M
dc.contributor.authorFabbri, A
dc.contributor.authorJohnson, P
dc.contributor.authorGørløv, J
dc.contributor.authorHess, G
dc.contributor.authorPanse, J
dc.contributor.authorPisani, F
dc.contributor.authorTucci, A
dc.contributor.authorStilgenbauer, S
dc.contributor.authorHertenstein, B
dc.contributor.authorKeller, U
dc.contributor.authorKrause, S
dc.contributor.authorLevis, A
dc.contributor.authorSchmoll, H
dc.contributor.authorCavalli, F
dc.contributor.authorFinke, J
dc.contributor.authorReni, M
dc.contributor.authorZucca, E
dc.contributor.authorIllerhaus, G
dc.date.accessioned2016-05-25T15:28:54Zen
dc.date.available2016-05-25T15:28:54Zen
dc.date.issued2016-05en
dc.identifier.citationChemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. 2016, 3 (5):e217-27 Lancet Haematolen
dc.identifier.issn2352-3026en
dc.identifier.pmid27132696en
dc.identifier.doi10.1016/S2352-3026(16)00036-3en
dc.identifier.urihttp://hdl.handle.net/10541/610746en
dc.description.abstractStandard treatment for patients with primary CNS lymphoma remains to be defined. Active therapies are often associated with increased risk of haematological or neurological toxicity. In this trial, we addressed the tolerability and efficacy of adding rituximab with or without thiotepa to methotrexate-cytarabine combination therapy (the MATRix regimen), followed by a second randomisation comparing consolidation with whole-brain radiotherapy or autologous stem cell transplantation in patients with primary CNS lymphoma. We report the results of the first randomisation in this Article.
dc.language.isoenen
dc.rightsArchived with thanks to The Lancet. Haematologyen
dc.titleChemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.en
dc.typeArticleen
dc.contributor.departmentUnit of Lymphoid Malignancies, Department of Onco-Hematology, IRCCS San Raffaele Scientific Institute, Milan, Italyen
dc.identifier.journalThe Lancet Haematologyen
dc.description.collectionLymphoma Research Teamen
html.description.abstractStandard treatment for patients with primary CNS lymphoma remains to be defined. Active therapies are often associated with increased risk of haematological or neurological toxicity. In this trial, we addressed the tolerability and efficacy of adding rituximab with or without thiotepa to methotrexate-cytarabine combination therapy (the MATRix regimen), followed by a second randomisation comparing consolidation with whole-brain radiotherapy or autologous stem cell transplantation in patients with primary CNS lymphoma. We report the results of the first randomisation in this Article.


Files in this item

This item appears in the following Collection(s)

Show simple item record